Allied Corp Successfully Ships First Commercial Cannabis Flower Export From Colombia to International Market
KELOWNA, British Columbia, June 29, 2022 (GLOBE NEWSWIRE) -- Allied Corp. ("Allied" or the “Company”) (OTCQB: ALID) is pleased to...
Year: 2022
Quotient Limited Announces Closing of Underwritten Offering of Ordinary Shares and Pre-Funded Warrants
JERSEY, Channel Islands, June 29, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (Nasdaq: QTNT) (the "Company"), a commercial-stage diagnostics company, announced...
Palisade Bio Initiates Phase 3 Study of LB1148 in Lead Indication for Postoperative Return of Bowel Function
Completion of enrollment for Phase 3 study targeted within 18-24 months In multiple clinical studies, LB1148 has demonstrated statistically significant...
SciSparc Successfully Completed The Development of its Proprietary Drug Candidate SCI-110 for its Upcoming Phase IIb Study In Tourette Syndrome
TEL AVIV, Israel, June 29, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty, clinical-stage...
Odyssey Health, Inc. Completes Safety Evaluation of Cohort II for Concussion Drug
Las Vegas, NV, June 29, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, Inc.,...
ALR Technologies Completes Definitive Manufacturing Agreement with Infinovo Medical for the GluCurve Pet CGM Hardware
SINGAPORE, June 29, 2022 (GLOBE NEWSWIRE) -- ALR Technologies SG Pte. Ltd (“ALRT” or the “Company”) (OTCQB: ALRT), the diabetes...
Novozymes’ financial calendar 2023
Read the full announcement in PDF Attachment 2022_24_Financial_calendar_2023
NeuBase Therapeutics Announces Promotion of Dr. William Mann to President and COO
PITTSBURGH and CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a...
Homology Medicines to Present at Upcoming Conferences on its Gene Editing and Gene Therapy Programs for PKU
BEDFORD, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today participation...
Publication Highlights Potential Clinical Applications of the HTG Transcriptome Panel in Bladder Cancer
TUCSON, Ariz., June 29, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing...
Windtree Is Leveraging Positive Istaroxime Early Cardiogenic Shock Results to Proactively Engage in Licensing Discussions and Explore Strategic Opportunities to Realize Greater Shareholder Value
Positive Data for Istaroxime in Early Cardiogenic Shock Brings Notable Interest from Potential Partners WARRINGTON, Pa., June 29, 2022 (GLOBE...
Alignment Healthcare to Expand to Florida and Texas to Reach 8.2 Million Medicare-eligible Adults across Six States
Medicare Advantage company to also introduce its award-winning health plans to new counties within Arizona, California, Nevada and North Carolina, pending...
Ventyx Biosciences Announces Positive Topline Phase 1 Data for its Peripheral NLRP3 Inhibitor VTX2735
Excellent safety, tolerability and pharmacokinetic profile Robust dose-dependent target engagement as measured by ex vivo IL-1β release assay Phase 2...
ProFound AI Risk Real-World Case Studies to be featured in iCAD’s “ProFound Insights, ProFound Impact” Webinar Series
Leading radiologists to highlight clinical examples demonstrating power of iCAD’s complete suite of ProFound AI Breast Health SolutionsNASHUA, N.H., June...
Catalyst Biosciences Announces Plan to Distribute Cash to Stockholders
Board is Committed to Maximizing the Amount of Cash the Company Distributes to Stockholders Decision Follows Recent Sale of Certain...
GBT Initiates Phase 2/3 Clinical Trial of GBT601 in Patients with Sickle Cell Disease
Phase 2 portion designed to identify the optimal dose for the pivotal Phase 3 portion of the trialSOUTH SAN FRANCISCO,...
Amolyt Pharma Strengthens Leadership Team with Appointment of Mark Sumeray, M.D., as Chief Medical Officer
Industry veteran brings over two decades of global experience in pharmaceutical, medical devices and biotech industriesLYON, France and CAMBRIDGE, Mass.,...
Humacyte Announces JAMA Surgery Publication Highlighting Potential of Human Acellular Vessel™ (HAV™) to Expand Vascular Trauma Reconstruction and Bypass Treatment Options
-- HAV implanted in nearly 500 patients with more than 1,000 patient-years of follow up to date, for treatment of...
Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer
Evaluation completed of first dose level in investigator-sponsored study in biochemically recurrent prostate cancer Enrollment initiated for second dose level...
Codiak Initiates Patient Dosing in Phase 1 Clinical Trial of exoASO™-STAT6 in Patients with Advanced Hepatocellular Carcinoma, Liver Metastases from Primary Gastric Cancer and Colorectal Cancer
exoASO-STAT6 is the third engineered exosome candidate generated from Codiak’s engEx® Platform to enter clinical development CAMBRIDGE, Mass., June 29,...